Table 1.
Summary of xenograft characteristics
| Basal-like xenograft (MAS98.12) | Luminal-like xenograft (MAS98.06) | |||
|---|---|---|---|---|
| Primary tumor | Xenograft | Primary tumor | Xenograft | |
| Tumor grade | Grade III IDC | NA | Grade III IDC | NA |
| Lymph node status | No metastasis | NA | Metastasis to 12 of 25 nodes | NA |
| No distant metastases | ||||
| Differentiation | Poorly differentiated | Poorly differentiated | Well differentiated | Poorly differentiated |
| Hormone receptor status | ER-/PgR+** | ER-/PgR- | ER+/PgR+ | ER+/PgR+ |
| ERBB2 amplification* | Negative | Negative | Negative | Negative |
| Intrinsic molecular subtype | Basal-like | Basal-like | Luminal-like | Luminal-like |
| TP53 status | Wildtype | Mutated | Mutated | Mutated |
| Volume doubling time | NA | 1-2 days | NA | 7 days |
| Proliferation index (Ki67) | Missing | 28% | Missing | 35% |
Summary of characteristics related to genotype and phenotype of the xenograft models
* Measured at the DNA level by array Comparative Genomic Hybridization (aCGH)
** The primary basal-like carcinoma had very weak cytoplasmic staining for PgR29.